Capital Research Institute of Pediatrics Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2015
NCT03654703
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Capital Research Institute of Pediatrics

Active Ingredients

Drugs in Phase 2 Trials (3)

cyclophosphamide (cytoxan) (1 trial)

dexamethasone (1 trial)

ruxolitinib (jakafi) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lymphohistiocytosis, Hemophagocytic (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 3